For instance, treatments approved for AD primarily compensate for the loss of cholinergic neurons and include the use of inhibitors of cholinesterases (ChE), such as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). This evidence concerns the gene BCHE and Alzheimer disease.